Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study
作者
Zhenluan Tian,Hengyu Li,Yuxin Deng,Herui Yao,Ying Wang,Liang Jin,Heran Deng,Na Chen,Jieqiong Liu